FDA Approves BUMETANIDE — Sandoz Inc

Sandoz Inc., a global healthcare leader, announced the approval of the oral formulation of Bumex (bumetanide) today, opening a new avenue for patients seeking generic diuretic therapy. This authorization is expected to increase market accessibility and intensify price competition within the loop diuretic segment of the pharmaceutical industry.